Rapport Therapeutics (RAPP) Other financing activities (2024 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Other financing activities of $273000.0 for Q1 2026, up 4450.0% year-over-year from $6000.0 in Q1 2025, and down 61.33% quarter-over-quarter from $706000.0 in Q4 2025.
Rapport Therapeutics (RAPP) Other financing activities (2024 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Other financing activities for 3 consecutive years, with $273000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 4450.0% year-over-year to $273000.0; the TTM figure through Mar 2026 stood at $1.6 million (changed N/A YoY), while the FY2025 annual figure was $1.3 million, up 19157.14% from the prior year.
- Other financing activities retreated to $273000.0 in Q1 2026 per RAPP's latest filing, from $706000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $706000.0 in Q4 2025 and bottomed at $6000.0 in Q1 2025.
- Historically, Other financing activities has averaged $380800.0 across 3 years, with a median of $283000.0 in 2024.
- Annual changes were most pronounced in 2025 — Other financing activities plunged 97.88% — and 2026, when it soared 4450.0%.
- Rapport Therapeutics' Other financing activities stood at $283000.0 in 2024, then soared by 149.47% to $706000.0 in 2025, then plunged by 61.33% to $273000.0 in 2026.
- Business Quant data shows RAPP's Other financing activities at $273000.0 in Q1 2026, $706000.0 in Q4 2025, and $636000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.59 Mn |
| Jun 30, 2026 | 1.59 Mn |
| Mar 31, 2026 | 273,000.00 |
| Mar 31, 2026 | 273,000.00 |
| Dec 31, 2025 | 706,000.00 |
| Dec 31, 2025 | 706,000.00 |
| Sep 30, 2025 | 636,000.00 |
| Sep 30, 2025 | 636,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Mar 31, 2024 | 283,000.00 |
| Mar 31, 2024 | 283,000.00 |